Allelic Variant Detection for ARM Risk Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying the risk of age-related maculopathy (ARM) are incomplete as they primarily focus on the complement factor H gene, failing to account for other genetic contributors to the disease's pathology, particularly in the eye.
Innovation Solution
Detection of allelic variants, including single nucleotide polymorphisms in the LOC387715 and PLEKHA1 genes on chromosome 10q26, which are associated with an increased risk of developing ARM, using nucleic acid amplification assays such as PCR or TAQMAN to identify thymine or guanine polymorphisms at specific bases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If only the complement factor H gene is tested for ARM risk identification, then the testing process is simple and focused, but the identification completeness and accuracy are insufficient
Solution Approach 1:
The patent segments the ARM risk identification process into two independent parts: testing for complement factor H gene variants and testing for chromosome 10q26 region variants (LOC387715 and PLEKHA1 genes). This segmentation allows each test to be optimized independently while collectively providing comprehensive risk assessment, resolving the contradiction between testing completeness and process simplicity.
Solution Approach 2:
The patent creates a universal ARM risk identification system that can accommodate multiple genetic loci through a standardized testing framework. The method universally applies to different gene regions (CFH and 10q26) using consistent nucleic acid amplification and detection procedures, enabling expanded coverage without proportionally increasing operational complexity.
2Reliability
If multiple genetic loci are tested for ARM risk, then the identification completeness improves, but the testing complexity and cost increase
Solution Approach 1:
The patent divides the genetic testing into separate modular assays for CFH and 10q26 regions, each with its own optimized protocols. This modular segmentation maintains high reliability through comprehensive coverage while managing complexity through standardized, repeatable procedures for each segment.
Solution Approach 2:
The patent employs different detection parameters and methodologies optimized for each genetic locus, such as specific primer designs and detection conditions for CFH versus 10q26 variants. This parameter optimization ensures high reliability for each test while maintaining overall system manageability through standardized frameworks.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
Allelic variations in the genes PLEKHA1 and LOC387715 are identified herein as risk factor for Age Related Maculopathy (ARM). A method is therefore provided for identifying a risk of development of ARM in an individual that comprises identification of allelic variations in PLEKHA1 and/or LOC387715. Related apparatus, such as an array, are identified as being useful in implementing those methods.